PMID- 11369057
OWN - NLM
STAT- MEDLINE
DCOM- 20010906
LR  - 20190816
IS  - 0165-4608 (Print)
IS  - 0165-4608 (Linking)
VI  - 125
IP  - 2
DP  - 2001 Mar
TI  - Proliferating cell nuclear antigen and epidermal growth factor receptor (EGFr) 
      status in renal cell carcinoma patients with polysomy of chromosome 7.
PG  - 139-46
AB  - We investigated 40 cases of renal cell carcinoma (RCC) to study the polysomy 7 
      status in papillary and clear-cell types (nonpapillary RCC) and relationship with 
      clinical, pathological, and biological features such as grade, stage, tumor 
      proliferation rate (PCNA expression) and epidermal growth factor receptor (EGFr) 
      expression and thereby to understand the prognostic significance of polysomy 7 
      and EGFr expression. In a prospective study, chromosome 7 copy number was 
      analyzed in tumor cells by using fluorescence in situ hybridization (FISH) with 
      an alpha-satellite DNA probe for chromosome 7. Both proliferating cell nuclear 
      antigen (PCNA) and EGFr expression were examined in paraffin sections by 
      immunostaining. The relationship between clinicopathological and 
      clinicobiological parameters was evaluated by appropriate statistical methods. 
      Polysomy 7 was present in 100% of papillary and 56.2% of clear-cell types RCC. In 
      clear-cell RCC, in comparison with polysomy 7-dominant (D) category (20-50% 
      polysomy-7 cells), polysomy 7-major (M) category (>50% polysomy 7 cells) was 
      associated with higher tumor grade (P = 0.05). Polysomy 7 was also correlated 
      with stage of the disease (P = 0.006). The PCNA index ranged between 12.8-89.6% 
      and was comparatively high in high-grade tumors (P = 0.001). The PCNA index was 
      also correlated with polysomy 7 (P = 0.002), and the association was stronger in 
      tumors with polysomy M versus polysomy D category (P = 0.02). The EGFr expression 
      did not correlate with either grade, stage, PCNA, or polysomy 7. The correlation 
      of polysomy 7 with less favorable prognostic factors such as higher tumor grade, 
      stage, and higher proliferative index in the present study indicates that 
      polysomy 7 might be used as a prognostic predictor in clear-cell RCC. Evaluation 
      of clinical end points will confirm the prognostic potential of the genetic 
      marker polysomy 7 in our study.
FAU - Amare Kadam, P S
AU  - Amare Kadam PS
AD  - Cytogenetic Laboratory, Department of Medical Oncology, Tata Memorial Hospital, 
      Dr. Ernest Borges Marg, Parel, 400012, Mumbai, India.
FAU - Varghese, C
AU  - Varghese C
FAU - Bharde, S H
AU  - Bharde SH
FAU - Narasimhamoorthy, N K
AU  - Narasimhamoorthy NK
FAU - Desai, S
AU  - Desai S
FAU - Advani, S H
AU  - Advani SH
FAU - Havaldar, R
AU  - Havaldar R
FAU - Kulkarni, J N
AU  - Kulkarni JN
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Genet Cytogenet
JT  - Cancer genetics and cytogenetics
JID - 7909240
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Proliferating Cell Nuclear Antigen)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Adenocarcinoma, Clear Cell/chemistry/genetics/pathology
MH  - Adult
MH  - Aged
MH  - *Aneuploidy
MH  - Biomarkers, Tumor/*analysis
MH  - Carcinoma, Papillary/chemistry/genetics/pathology
MH  - Carcinoma, Renal Cell/chemistry/*genetics/pathology
MH  - Cell Division
MH  - *Chromosome Aberrations
MH  - *Chromosomes, Human, Pair 7
MH  - ErbB Receptors/*analysis/genetics
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Interphase
MH  - Kidney Neoplasms/chemistry/*genetics/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Proteins/*analysis/genetics
MH  - Neoplasm Staging
MH  - Proliferating Cell Nuclear Antigen/*analysis/genetics
EDAT- 2001/05/23 10:00
MHDA- 2001/09/08 10:01
CRDT- 2001/05/23 10:00
PHST- 2001/05/23 10:00 [pubmed]
PHST- 2001/09/08 10:01 [medline]
PHST- 2001/05/23 10:00 [entrez]
AID - S0165-4608(00)00375-7 [pii]
AID - 10.1016/s0165-4608(00)00375-7 [doi]
PST - ppublish
SO  - Cancer Genet Cytogenet. 2001 Mar;125(2):139-46. doi: 
      10.1016/s0165-4608(00)00375-7.